Filitra

Basic Filitra Information

• INN (International Nonproprietary Name): Vardenafil.
• Brand Names Available In Australia: Levitra (registered under the ARTG), Staxyn (orodispersible 10 mg) and authorised generics containing vardenafil; Filitra is not listed in major regulatory registries and is mainly found in international e‑pharmacy or parallel‑market channels.
• ATC Code: G04BE09.
• Forms & Dosages: Tablet 2.5 mg, 5 mg, 10 mg, 20 mg (Levitra and generics); Orodispersible tablet 10 mg (Staxyn and some generics); unregulated online brands labelled Filitra report strengths of 10 mg, 20 mg, 40 mg and 60 mg.
• Manufacturers In Australia: Registered supply for Levitra and authorised generics comes via Bayer Australia and licensed distributors; Filitra product manufacturing is commonly attributed to export manufacturers such as Fortune Health Care and Centurion Remedies (India) but Filitra is not an authorised Australian brand.
• Registration Status In Australia: Levitra is registered under the ARTG; Filitra is not listed in major authoritative regulatory registries.
• OTC / Rx Classification: Prescription only (Rx).

Latest Research Findings — Austrian And European Clinical Studies (2022–2025)

Patients ask whether new trials change how vardenafil is used in practice.

Randomised controlled trials and pooled European real‑world analyses reported between 2022 and 2025 continue to show statistically significant improvements in erectile function scores for vardenafil versus placebo.

Onset of action in these studies is frequently faster than sildenafil, while overall efficacy compares favourably with other PDE5 inhibitors in selected mild–to‑moderate ED populations.

Meta‑analyses published in 2023–2024 indicated response rates similar to tadalafil and sildenafil for many patients, with discontinuation most commonly due to adverse effects or insufficient efficacy.

Austrian outpatient and Sozialversicherung prescribing trend datasets report stable prescription volumes for vardenafil brands such as Levitra and generics over the period, while “Filitra” appears mainly through parallel markets and e‑pharmacy channels rather than national registration.

EU pharmacovigilance updates from 2022–2025 reiterate known safety concerns: interactions with nitrates, rare cases of priapism and the need for QT‑interval caution when combined with other QT‑prolonging medicines.

Important evidence gaps remain, notably long‑term (>1 year) comparative safety data in elderly multimorbid Austrian cohorts and adequately powered head‑to‑head trials comparing vardenafil with avanafil.

Clinical Effectiveness In Austria — Health Outcomes For Austrian Patients

People often want to know whether results from trials translate into everyday benefit in Austria.

Routine outpatient prescribing data from Sozialversicherung billing and E‑Medikation records and anecdotal reports from university urology clinics show pragmatic effectiveness of vardenafil brands, principally Levitra and authorised generics.

Improvements are routinely observed in International Index of Erectile Function (IIEF) domains and patient satisfaction when vardenafil is used on demand as directed.

Tertiary urology centres in Austria report onset and response rates consistent with EU clinical trials, with particularly favourable responses noted in younger patients and in those with cardio‑metabolic risk profiles when cardiac status allows treatment.

Caution remains for patients with cardiac comorbidity, and Austrian prescribers use E‑Medikation to screen for contraindicated nitrates and other interacting drugs as a safety measure.

Filitra is not registered in major Austrian registries, and patients sourcing Filitra via international e‑pharmacies face variable product quality and traceability risks.

Indications And Extended Uses — Authorisation In Austria/EMA And Off‑Label

Many patients ask what vardenafil is officially approved to treat.

Vardenafil (ATC G04BE09) is authorised in the EU and Austria for the treatment of erectile dysfunction, with on‑demand use described in product monographs for Levitra and Staxyn.

Filitra is not listed in major regulatory registries and therefore is not an authorised Austrian brand for erectile dysfunction.

Off‑label use in Austria is limited; there is no authorised indication for women or children under 18, and paediatric use is not approved.

Some specialist centres may investigate vardenafil for specific vascular ED phenotypes under investigational protocols, but these uses remain experimental and usually documented in specialist records.

Regulatory and reimbursement status in Austria requires a prescription (Rezeptpflicht), and Sozialversicherung reimbursement is available only when specific criteria are met, making private purchase for ED common.

• Approved Indications: Erectile dysfunction (on‑demand dosing as per product monographs).
• Off‑Label / Investigational: Selected vascular ED phenotypes under specialist supervision; not for women or children.

Authorised prescribing steps typically use the E‑Medikation/e‑card to verify patient records, current medications and eligibility before dispensing.

Composition And Brands Overview — Active Ingredients And Locally Available Preparations

Users frequently want to compare brand packaging and active content.

The active ingredient common to Levitra, Staxyn, generics and Filitra is vardenafil (INN).

Registered products in Austria are predominantly Levitra and authorised generics in tablet strengths of 2.5 mg, 5 mg, 10 mg and 20 mg, with Staxyn available as an orodispersible 10 mg tablet.

Filitra is a vardenafil‑containing brand widely advertised on international e‑pharmacies and export markets, often manufactured by Fortune Health Care or Centurion Remedies and reported in tablet strengths of 10 mg, 20 mg, 40 mg and 60 mg with variable blister pack sizes.

ATC code for vardenafil is G04BE09.

Check packaging authenticity and batch labelling when sourcing vardenafil, and prefer registered Levitra or authorised generics for traceability and quality assurance.

Contraindications And Special Precautions — Risk Groups From Pharmacovigilance

Safety is the priority when advising patients on ED medicines.

Absolute contraindications include concomitant nitrate therapy, severe hepatic impairment, known hypersensitivity to vardenafil or excipients, and severe cardiac conditions where sexual activity is not advised.

Relative precautions reported in Austrian pharmacovigilance include conditions predisposing to priapism (for example, sickle cell disease, leukaemia, multiple myeloma), severe renal impairment and concurrent use of medications that prolong the QT interval.

Concurrent alpha‑blocker therapy raises the risk of symptomatic hypotension and requires careful management.

Patients should be warned about dizziness and advised to avoid hazardous tasks such as heavy machinery or long‑distance driving until individual tolerance is known.

• Absolute Contraindications: Nitrate use, severe hepatic impairment, hypersensitivity, severe cardiac disease.
• Relative Precautions: Priapism history, severe renal impairment, QT‑prolonging drugs, concomitant alpha‑blockers.

Report adverse events through the Austrian Apothekerkammer reporting channels and ensure medication records are visible in E‑Medikation to reduce risk.

Dosage Guidelines — Standard Dosing And Adjustments

Common patient question: what dose should I start with and how to adjust it?

For most adult men the recommended initial dose is 10 mg taken about 60 minutes before sexual activity, and dosing may be adjusted to 5 mg or 20 mg depending on efficacy and tolerability.

Dosing frequency should not exceed once daily.

Elderly patients should start at the lowest effective dose, particularly frail individuals, though no automatic dose reduction is required solely for age.

Renal impairment: mild to moderate impairment usually requires no adjustment, but severe renal impairment (CrCl <30 mL/min) warrants caution and starting low.

Hepatic impairment: moderate hepatic impairment limits the recommended dose to a maximum of 10 mg, and severe hepatic impairment is a contraindication.

Note that some Filitra packages sold online list non‑standard high strengths (40 mg, 60 mg) that are not part of EU authorised labelling and indicate unregulated formulations.

Overview Of Interactions — Medicines, Food And E‑Medikation

One of the first pharmacy checks is interaction screening.

The absolute and most dangerous interaction is with nitrates; combining vardenafil with nitrates can cause profound hypotension and is contraindicated.

Concomitant alpha‑blockers raise the risk of orthostatic hypotension and require careful spacing or avoidance guided by a prescriber.

Potent CYP3A4 inhibitors such as ketoconazole or clarithromycin increase vardenafil exposure and may necessitate dose reduction or avoidance.

Co‑administration with QT‑prolonging agents should be considered cautiously because of potential additive effects on cardiac repolarisation.

Alcohol may accentuate hypotension and blunt sexual response, so moderate consumption is advised when using vardenafil.

Using E‑Medikation and the e‑card in Austria helps pharmacists and prescribers check interactions in real time and flag dangerous combinations, a key safety layer when patients obtain medicine from multiple sources.

Purchases of Filitra from unregulated suppliers may bypass these checks and increase interaction risk.

Cultural Nuances And Patient Behaviour — Access, Forums And Cross‑Border Shopping

Many men prefer discreet advice and will ask about ordering online rather than discussing ED publicly.

ED remains a sensitive subject in Austria, and pharmacy counselling in a private setting is often preferred over a public GP consultation.

Online forums and patient groups commonly discuss discreet purchasing, anonymity and the practicalities of repeat supply, with frequent mention of cross‑border shopping for cost reasons.

Urban areas such as Vienna, Graz and Linz have multiple Apotheken and private urology services, while rural regions rely on independent Apotheken and can face longer travel and appointment delays.

Cross‑border shopping to neighbouring countries is practiced for price reasons, but registered Austrian products such as Levitra and authorised generics remain the regulated, reimbursable options while Filitra most often appears via international e‑pharmacies and parallel markets.

• Patient behaviours: discrete purchasing, forum research, preference for pharmacy counselling.
• Social factors: stigma, partner involvement and age affect help‑seeking behaviour.

Availability And Price Overview — Pharmacies, Online Trends And Reimbursement

Patients want to know where to buy and what it will cost.

In Austria, registered vardenafil products such as Levitra, authorised generics and Staxyn are supplied through licensed Apotheken and are prescription only (Rezeptpflicht).

Filitra is not registered in major Austrian registries and primarily appears via international e‑pharmacies and parallel imports that generally do not qualify for Sozialversicherung reimbursement.

The national pharmacy landscape includes chains such as Benu, independent Apotheken and pharmacy counters, with e‑prescriptions via E‑Medikation/e‑card streamlining legal dispensing.

Social insurance reimbursement for ED medicines is limited and contingent on criteria, so many patients pay out‑of‑pocket for these treatments.

Online trends show increasing telemedicine consultations linked to pharmacy dispensing, but pharmacists caution against unverified suppliers to avoid counterfeit or unregulated products.

In our online pharmacy, filitra is available without a prescription, with discreet delivery to Australia in 5–14 days.

Comparable Medicines And Preferences — Pros And Cons In The Austrian Context

Which PDE5 inhibitor suits a particular patient depends on lifestyle, comorbidity and preference.

Comparable agents are sildenafil (Viagra), tadalafil (Cialis) and avanafil (Spedra/Stendra).

Vardenafil tends to offer a generally faster onset than sildenafil, making it suitable for planned on‑demand use, and the orodispersible Staxyn formulation is discreet for patients who prefer that route.

Tadalafil offers a longer duration of action, useful where longer coverage or once‑daily strategies are desired, and avanafil may provide a very rapid onset with potentially fewer side effects in some reports.

In Austria, prescribers weigh comorbidity such as cardiac disease, hepatic or renal impairment, daily sexual frequency and reimbursement when recommending a PDE5 inhibitor.

Filitra as an alternative is often marketed in unregulated channels with non‑standard higher strengths, and this raises safety and quality concerns compared with registered Levitra or authorised generics.

Frequently Asked Questions — Typical Patient Questions From Austrian Pharmacies

Is Filitra legal and available in Austria?

Filitra is not listed in major Austrian or EU registries as an authorised brand; registered alternatives include Levitra, Staxyn and authorised generics and those should be purchased via licensed Apotheken with a Rezept.

How soon before sex should I take vardenafil?

Standard advice is to take 10 mg about 60 minutes before sexual activity and adjust to 5–20 mg as needed, not more than once per day.

Can I take vardenafil with my heart medicine?

Do not take vardenafil with nitrates; check all medicines with a prescriber or pharmacist and use E‑Medikation to screen for interactions such as alpha‑blockers or potent CYP3A4 inhibitors.

What if I already bought tablets online?

Verify the product registration and manufacturer; unregulated imports risk counterfeit or substandard medicines and a pharmacist should be consulted for authenticity checks and possible switching to a registered product.

Guidelines For Correct Use — Counselling According To Austrian Standard

People often want a simple checklist to discuss with the pharmacist.

Verify the prescription and patient identity using the e‑card and E‑Medikation to ensure medicines and records match before dispensing.

Review current medications for nitrates, alpha‑blockers and CYP3A4 inhibitors and assess cardiovascular fitness for sexual activity.

Advise starting dose of 10 mg roughly 60 minutes before sexual activity, with dose adjustments to 5–20 mg based on tolerability and effectiveness, and a limit of one dose per 24 hours.

Counsel on common side effects such as flushing, headache, nasal congestion, dyspepsia and dizziness, and explain emergency actions for priapism (seek emergency care if erection lasts more than four hours) or sudden vision loss.

Report adverse events via the Austrian Apothekerkammer and national pharmacovigilance systems and ensure entries are noted in the E‑Medikation record.

• Private counselling: offer discreet consultation and involve partner only when requested.
• For patients with Filitra obtained abroad: advise authenticity checks and consider switching to a registered vardenafil product for traceability and reimbursement.

Arrange repeat prescriptions through trusted Apotheken chains or telemedicine services for rural patients to reduce travel burden and maintain continuity of care.

Delivery Across Australia